CRNX
Price
$55.48
Change
+$1.17 (+2.15%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
5.57B
49 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$8.32
Change
+$0.81 (+10.79%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
2.13B
64 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs ERAS

Header iconCRNX vs ERAS Comparison
Open Charts CRNX vs ERASBanner chart's image
Crinetics Pharmaceuticals
Price$55.48
Change+$1.17 (+2.15%)
Volume$17.67K
Capitalization5.57B
Erasca
Price$8.32
Change+$0.81 (+10.79%)
Volume$194K
Capitalization2.13B
CRNX vs ERAS Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. ERAS commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CRNX: $54.31 vs. ERAS: $7.51)
Brand notoriety: CRNX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 62% vs. ERAS: 234%
Market capitalization -- CRNX: $5.57B vs. ERAS: $2.13B
CRNX [@Biotechnology] is valued at $5.57B. ERAS’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRNX and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • ERAS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and ERAS are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а +18.19% price change this week, while ERAS (@Biotechnology) price change was +106.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 04, 2026.

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.57B) has a higher market cap than ERAS($2.13B). ERAS YTD gains are higher at: 101.747 vs. CRNX (16.670). ERAS has higher annual earnings (EBITDA): -131.32M vs. CRNX (-474.16M). CRNX has more cash in the bank: 1.09B vs. ERAS (288M). ERAS (48.3M) and CRNX (49.1M) have identical debt. CRNX has higher revenues than ERAS: CRNX (1.54M) vs ERAS (0).
CRNXERASCRNX / ERAS
Capitalization5.57B2.13B261%
EBITDA-474.16M-131.32M361%
Gain YTD16.670101.74716%
P/E RatioN/AN/A-
Revenue1.54M0-
Total Cash1.09B288M379%
Total Debt49.1M48.3M102%
FUNDAMENTALS RATINGS
CRNX: Fundamental Ratings
CRNX
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
41
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRNXERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
76%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNREX13.320.06
+0.45%
Dunham Real Estate Stock N
GSSUX39.890.09
+0.23%
Goldman Sachs Small Cap Value R6
ALVIX10.60N/A
N/A
American Century Focused Lg Cap Val Inv
SEVSX40.73-0.09
-0.22%
NAA SMid Cap Value C
TWCGX57.30-0.15
-0.26%
American Century Growth Inv

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.88%
XNCR - CRNX
59%
Loosely correlated
-1.62%
RVMD - CRNX
54%
Loosely correlated
+2.37%
IDYA - CRNX
51%
Loosely correlated
-4.75%
KURA - CRNX
50%
Loosely correlated
+0.44%
CLDX - CRNX
50%
Loosely correlated
+1.01%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+20.47%
RVMD - ERAS
61%
Loosely correlated
+2.37%
NUVL - ERAS
48%
Loosely correlated
+2.03%
ZNTL - ERAS
47%
Loosely correlated
-0.29%
CRNX - ERAS
47%
Loosely correlated
-1.88%
OCUL - ERAS
46%
Loosely correlated
-2.43%
More